Skip to main content

PhotoCure

Photocure ASA is a Norwegian specialty pharmaceutical company focused on photodynamic technology for bladder cancer diagnosis and management. The company develops and commercializes Hexvix and Cysview, optical imaging agents used with blue light cystoscopy to detect non-muscle invasive bladder cancer. Main revenue drivers include commercial sales of Hexvix and Cysview kits to hospitals and clinics alongside partner royalty fees. Photocure serves urologists, hospital surgical departments, diagnostic centers, and bladder cancer patients across North America, Europe, and international markets. The company holds a market-leading position as a global pioneer in photodynamic diagnosis of bladder cancer. Headquartered in Oslo, Norway, Photocure ASA is listed on Oslo Bors.

7 of the funds FundTelligence covers report a position in PhotoCure.

Legal name
PhotoCure ASA
Sector
Health Care
Country
Norway
Funds holding it
7

Funds holding PhotoCure

Loading...